Sex: U
Vaccine: UNK, VARZOS
Symptoms: Asthenia, Erythema, Herpes ophthalmic, Herpes zoster cutaneous disseminated, Loss of personal independence in daily activities
Clinical narrative: rash; Vaccination failure / First dose was Sept 28, 2019; second was January 28, 2020; feels like herpes is now in my eyes; shingles/left hand, and around mouth/spread to involve my arm and forehead/area on my leg/not been limited to one area (dermatome)/all over my face/worst over my eyebrow/herpes zoster/brows, forehead, chin, nose, sides of nose, and under nose; redness; swelling; extremely debilitating; limited my ability to get exercise; This case was reported by a consumer and described the occurrence of vaccination failure in a adult patient who received Herpes zoster (Shingrix) for prophylaxis.   Previously administered products included Shingrix (1st dose received on 28th September 2019).   On 28th January 2020, the patient received the 2nd dose of Shingrix. On 1st March 2020, 33 days after receiving Shingrix, the patient experienced vaccination failure (serious criteria GSK medically significant), herpes ophthalmic (serious criteria GSK medically significant) and shingles. On 5th March 2020, the patient experienced rash. In March 2020, the patient experienced erythema, swelling, debility and activities of daily living impaired. The patient was treated with antivirals nos. On an unknown date, the outcome of the vaccination failure was unknown and the outcome of the herpes ophthalmic, shingles, rash, erythema, swelling, debility and activities of daily living impaired were not recovered/not resolved.   It was unknown if the reporter considered the vaccination failure, herpes ophthalmic, shingles, rash, erythema, swelling, debility and activities of daily living impaired to be related to Shingrix.  Additional case details were reported as follows: The patient reporter case for himself or herself. The age at vaccination was not reported. The age group was not reported, but was selected adult as per vaccine indication. Beginning a month after the second dose of Shingrix, patient experienced symptoms of shingles, which continued to worsen over a period of five months. Two areas were initially affected (left hand, and around mouth), but the symptoms spread to involve on arm and forehead. After five months, most of the active symptoms receded. For a few weeks, patient thought it was over. Then more symptoms appeared, with a new area on my leg. When these symptoms were over, patient had another brief time with no new and only slight residual symptoms, but then more symptoms, which were worse symptoms, and patient still dealing with them. The symptoms began the first days of March, 2020, with rash apparent on 5th March 2020.  Unlike a typical wild case of zoster, these symptoms was not limited to one area (dermatome), nor limited to one side. Currently the symptoms were all over patient's face, with the worst over eyebrows. This was also one of the first areas affected.  Although the original symptoms over the brows improved, redness and swelling was persisted there since March 2020, and in the most recent outbreak, the brow symptoms were worse than during any preceding outbreak. The face symptoms in this most recent outbreak involved both sides, including the brows, forehead, chin, nose, sides of nose, and under nose. The patient also spend considerable dollars during this time of unemployment (due to COVID-19) on medications that his or her physician had prescribed to lessen symptoms and help heal the outbreaks. While the antiviral definitely was necessary to get the symptoms under control, it had its own difficult effects.  The combination of antiviral and zoster had been extremely debilitating. Avoiding soon for such a long period and also had limited patient's ability to get exercise, which could help him or her immune system recover from the onslaught. The reporter requesting consent to follow up.